Treatments for melanoma are of two main types: targeted therapies and immune checkpoint inhibitors. However, both are only effective in a subset of patients and are limited by acquired resistance. Here, the authors present the preclinical basis to broadly target different forms of therapy-resistant melanoma.
https://ift.tt/2k5B9vc
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου